Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: The M.D. Anderson Cancer Center experience

Breast Cancer Research and Treatment

Volumn 54, Issue 3, 1999, Pages 225-233

  Cristofanilli, Massimo ^a   Holmes, Frankie Ann ^a   Esparza, Laura ^a   Valero, Vicente ^a   Buzdar, Aman U ^a   Neidhart, James A ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cardiac toxicity; Dose intensity; Metastatic breast cancer; Mitoxantrone; Myelosuppression; Single agent chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MITOXANTRONE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTE; GRANULOCYTOPENIA; HOSPITALIZATION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADULT; ALGORITHMS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS;

EID: 0033054419     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006104610727     Document Type: Article

References (35)

1. 1. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yoa TJ, Lepore J, Gilewsy T, Currie V, Crown J, Norton L: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581, 1995
2. 2. Gelmon K: The taxoids: Paclitaxel and docetaxel. Lancet 344: 1267-1272, 1994
3. 3. Chevallier B, Fumoleau P, Kerbrar P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322, 1995
4. 4. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45: 12, 1995
5. 5. Henderson IC: Chemotherapy for metastatic disease. In: Harris J, Hellmann S, Henderson IC, Kinne DW (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1991, pp 604-664
6. 6. Hryniuk W, Figueredo A, Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14 (suppl 4): 3-11, 1987
7. 7. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253-1259, 1994
8. 8. Jones RB, Holland JF, Bhardwaj S, Norton L, Wilfinger C, Strashun A: A phase I/II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5: 172-177, 1987
9. 9. Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Holmes F: Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomycardial biopsy: An update. Invest New Drugs 3: 117-121, 1985
10. 10. Allegra JC, Woodcock T, Woolf SN, Henderson IC, Bryan S, Reisman A, Dukart G: A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3(2): 153-161, 1985
11. 11. Cowan JD, Osborne CK, Neidhart JA, Von Hoff DD, Constanzi JJ, Vaughn CB: Randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs 3(2): 149-152, 1985
12. 12. Coleman RE, Maisey MN, Knight RK, Rubens RD: Mitoxantrone in advanced breast cancer - a Phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 20: 771-776, 1981
13. 13. Yap HY, Blumenschein G, Schell F, Buzdar AU, Valdivieso M, Bodey GP: Dihydroxyanthracenedione: A promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95: 694-697, 1981
14. 14. Knight WA III, Von Hoff D, Tranum B, O'Brien R. Phase II trial of dihydroxyanthracenedione (DHAD, mitoxantrone) in breast cancer: A Southwest Oncology Group (SWOG) study (Abstract). Proc Am Soc Clin Oncol 1: 87, 1982
15. 15. Levin M, Pandya KJ, Khandekar JD, Horton J, Glick JH, Bennett JM, Muggia FM, Falkson G: Phase II study of mitoxantrone in advanced breast cancer: An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 68: 1511-1512, 1984
16. 16. Smalley R, Gams R: Phase II study of mitoxantrone in patients with metastatic breast carcinoma: A Southeastern Cancer Study Group project. Cancer Treat Rep 67: 1039-1040, 1983
17. 17. de Jager R, Cappelaere P, Earl H, Rubens R, Stuart Harris R, Smith I, Carmichael J, Smythe J, Keiling R, Renard J, van Glabbeke M, Mathe G: Phase II clinical trial of mitoxantrone (1,4-dihydroxy-5-8-bis (2-2-hydroxyethyl amino) 9, 10 anthracenedione dihydrochloride) in solid tumors and lymphomas (Abstract). Proc Am Soc Clin Oncol 1: 89, 1982
18. 18. Wilson KS, Paterson AHG: Single agent mitoxantrone as first line chemotherapy in advanced breast cancer (Abstract). Proc Am Soc Clin Oncol 3: 117, 1984
19. 19. Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R, McDonald M, Rainer H, van Oosterom A, Smyth JF: Mitoxantrome as first-line chemotherapy in advanced breast cancer: Results of a collaborative European study. Invest New Drugs 3: 139-148, 1985
20. 20. Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H, van Oosterom A, Smyth JF: Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol 20: 1141-1146, 1984
21. 21. Landys K, Borgstrom S, Andersson T, Noppa H: Mitoxantrone as a first-line treatment of advanced breast cancer. Invest New Drugs 3: 133-137, 1985
22. 22. Neidhart JA, Gochnour D, Roach R, Hoth U, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 627-677, 1986
23. 23. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1989
24. 24. Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LK, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J Natl Cancer Inst 83: 1077-1084, 1991
25. 25. Von Hoff DD, Coltman CA, Forseth B: Activity of mitoxantrone in human tumor cloning assay. Cancer Res 41: 1853-1855, 1981
26. 26. Shenkenberg TD, Von Hoff DD: Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med 105:67-81, 1986
27. 27. Leiby JM, Unverfurth DV, Neidhart JA: High dose mitoxantrone in metastatic breast cancer: A phase I/II trial. Cancer Treat Rep 70: 899-901, 1986
28. 28. Shpall EJ, Jones RB, Holland JF, Bhardwaj S, Paciucci PA, Wilfinger CL, Strashun A: Intensive single-agent mitoxantrone for metastatic breast cancer. J Natl Cancer Inst 80: 204-208, 1998
29. 29. Legha SS, Benjamin RS, MacKay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133-139, 1982
30. 30. Durr FE: Biologic and biochemical effects of mitoxantrone. Semin Oncol 11: 3-10, 1984
31. 31. Lenk H, Muller U, Tanneberger S: Mitoxantrone: Mechanism of action, antitumor activtiy, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7: 1257-1264, 1987
32. 32. Demetri GD, Horowitz J, McGuire BW, Merica EA, Howard G, Henderson IC: Dose-intensification of mitoxantrone with adjunctive G-CSF(r-metHu-G-CSF) in patients with advanced breast cancer: A phase I trial (Abstract). Proc Am Soc Clin Oncol 11: 137, 1992
33. 33. Dukart G, Posner L, Henry D et al.: Comparative toxicity of mitoxantrone vs. doxorubicin (Abstract). Proc Am Soc Clin Oncol 5: 48, 1986
34. 34. Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G: Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep 66: 1641-1643, 1982
35. 35. Vermorken JB, ten Bakkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijen JH, Bierhorsth F, Wingrad B, Pinedo HM: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy. Semin Oncol 22 (suppl 8): 16-22, 1995